

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 19, 2002, 12:55:37 ; Search time 291.77 Seconds  
(without alignments)  
5260.724 Million cell updates/sec

Title: US-09-788-476a-1  
Perfect score: 894  
Sequence: 1 gggagtgaggagtgagggttaa.....taataaaaaaaaaatagaataa 894

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues  
Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
N\_Geneseq\_032802.\*  
1: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*  
2: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*  
3: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*  
4: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*  
5: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*  
6: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*  
7: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*  
8: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*  
9: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*  
10: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*  
11: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*  
12: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*  
13: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*  
14: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*  
15: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*  
16: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*  
17: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*  
18: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*  
19: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*  
20: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*  
21: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*  
22: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.\*  
23: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*  
24: /SIDSL1/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	894	100.0	1154	22 AAS29109
2	891	99.7	1071	22 AAC88100
3	869.4	97.2	891	24 AAS62602
4	467.6	52.3	471	21 AAC00738
5	334	37.4	408	22 AAH81555
6	281.4	31.5	5469	22 AAL137635
7	281.4	31.5	5469	22 ABA08032
8	281.4	31.5	5469	22 AAL06683
9	281.4	31.5	5469	22 AAK84119

C 10	281.4	31.5	9453	22 AAL37634	Human musculostele
C 11	281.4	31.5	9453	22 ABA08021	Human ovarian and
C 12	281.4	31.5	9453	22 AAL06682	Human reproductive
C 13	281.4	31.5	9453	22 AAK84118	Human immune/haema
C 14	258.6	28.9	266	20 AAV89379	EST clone C1152.
C 15	231.2	25.9	591	20 AAX85623	Novel cDNA sequenc
C 16	211.8	23.7	255	22 AAH82022	Rat differential t
C 17	55.4	6.2	1686	16 AAO87587	DNA encoding leuco
C 18	55	6.2	399	23 AAS90682	DNA encoding novel
C 19	54	6.2	399	23 AAS93406	DNA encoding novel
C 20	54	6.0	5659	24 ABL32375	Human immune syste
C 21	54	6.0	5659	24 ABL34487	Human metastasis a
C 22	53.6	6.0	591	23 AAS70521	DNA encoding novel
C 23	53.6	6.0	591	23 AAS70706	DNA encoding novel
C 24	53.6	6.0	591	23 AAS90721	DNA encoding novel
C 25	53.6	6.0	1416	23 AAS67163	DNA encoding novel
C 26	53.6	6.0	3211	18 AAT89346	Human p160 CDNA 16
C 27	53.6	6.0	3901	18 AAT89345	Human p160 CDNA 16
C 28	52.6	5.9	29392	19 AAV15422	Mouse poly Ig rece
C 29	52.2	5.8	2334	23 AAS90705	DNA encoding novel
C 30	52	5.8	510	23 AAS69539	DNA encoding novel
C 31	52	5.8	510	23 AAS71141	DNA encoding novel
C 32	52	5.8	510	23 AAS90687	DNA encoding novel
C 33	51.4	5.7	2187	23 AAS75468	DNA encoding novel
C 34	51.4	5.7	2347	23 AAS75464	DNA encoding novel
C 35	51.4	5.7	2482	23 AAS90736	DNA encoding novel
C 36	51.2	5.7	305	22 ABA48950	Human breast cell
C 37	51.2	5.7	305	22 ABA66871	Human foetal liver
C 38	51.2	5.7	305	22 ABA33942	Probe #12408 for g
C 39	51.2	5.7	305	22 AAK15306	Human brain expres
C 40	51.2	5.7	305	22 AAK1027	Human bone marrow
C 41	51.2	5.7	305	22 AAT21797	Probe #11730 for g
C 42	51.2	5.7	305	22 AAT47083	Probe #15769 used t
C 43	51.2	5.7	305	22 AAT07480	Probe #7471 used t
C 44	51.2	5.7	496	22 ABA3847	Human breast cell
C 45	51.2	5.7	496	22 ABA54309	Human foetal liver

ALIGNMENTS

RESULT 1	
AAS29109	Standard; CDNA: 1154 BP.
ID	AAS29109
XX	
AC	AAS29109;
XX	
DT	21-NOV-2001 (first entry)
XX	
DE	CDNA encoding for human DNA-binding protein #80.
XX	
KW	Human; DNA-binding protein; histone; chromo domain protein;
KW	Chromatin organisation modifier; Y-box binding protein;
KW	DNA organisation; gene transcription; malignant disease;
KW	autoimmune disorder; rheumatic disease; genetic abnormality;
KW	infectious disease; neurological disorder; gene therapy;
KW	immunomodulatory; anti-HIV; anti rheumatic; anti microbial;
KW	cytostatic; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO20015162-A1.
XX	
PD	02-AUG-2001.
XX	
PF	17-JAN-2001; 2001WO-US01305.
XX	
PR	31-JAN-2000; 2000US-0179065.
XX	
PR	04-FEB-2000; 2000US-0180628.
XX	
PR	24-FEB-2000; 2000US-0184664.
XX	
PR	02-MAR-2000; 2000US-0186350.
XX	
PR	16-MAR-2000; 2000US-0189874.
XX	
PR	17-MAR-2000; 2000US-0190076.





CC diseases or conditions associated with altered expression of functional  
 CC FLEXHT. The proteins and polynucleotides can be used to diagnose and  
 CC treat disorders including anaemia, epilepsy, arteriosclerosis,  
 CC atherosclerosis, developmental disorders, cancers, and immunological  
 CC disorders such as asthma, bronchitis, cirrhosis, Crohn's disease,  
 CC diabetes mellitus, gout, Grave's disease, multiple sclerosis,  
 CC osteoarthritis, pancreatitis, psoriasis, rheumatoid arthritis, and  
 CC ulcerative colitis.

SO Sequence 1071 BP; 338 A; 190 C; 297 G; 246 T; 0 other;

Query Match 99.7%; Score 891; DB 22; Length 1071;  
 Best Local Similarity 100.0%; Pred. No. 4.6e-229;  
 Matches 891; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 agtggagagaggggttaaaagatgagccgagagagtgagagcttcataagtaagctt 63  
 DB 163 agtggagagaggggttaaaagatgagccgagagagtgagagcttcataagtaagctt 222  
 QY 64 gccgaactaaagcaagaatgtcttctgtgtgtgtgtgagacccaaggaataagaat 123  
 DB 223 gccgaactaaagcaagaatgtcttctgtgtgtgtgtgagacccaaggaataagaat 282  
 QY 124 ctatccacagactccaggaatcttgaagaacatgtctgaagagaggaataagaat 183  
 DB 283 ctatccacagactccaggaatcttgaagaacatgtctgaagagaggaataagaat 342  
 QY 184 gctgactcggagatgagagaggaagaagaagaagccatgagcttccttctcaaa 243  
 DB 343 gactgaacggagagagagagaggaagaagaagaagccatgagcttccttctcaaa 402  
 QY 244 gaggaagagacccctgtaaaaaactgttattgtgtgagcagagagaagaagtggtgaat 303  
 DB 403 gaggaagagacccctgtaaaaaactgttattgtgtgagcagagagaagaagtggtgaat 462  
 QY 304 acatctgaataccacagactgtgagagaatgcagaagaagggctgaagatccaatgtacct 363  
 DB 463 acatctgaataccacagactgtgagagaatgcagaagaagggctgaagatccaatgtacct 522  
 QY 364 gtgagcttgagagaggaagaagctgtctggcagagtaagttggagattcttcagtcca 423  
 DB 523 gtgagcttgagagaggaagaagctgtctggcagagtaagttggagattcttcagtcca 582  
 QY 424 acaaaagctgcctcagtaacaacactatgtttaacttgaataagctgaaggaaga 483  
 DB 583 acaaaagctgcctcagtaacaacactatgtttaacttgaataagctgaaggaaga 642  
 QY 484 gctcaagaattgtgttgaatgtcttccaatctccagaagaagctgaagatgaga 543  
 DB 643 gctcaagaattgtgttgaatgtcttccaatctccagaagaagctgaagatgaga 702  
 QY 544 ctgaaagaagagagagagagcttggagttgcaacagttcagcggagactgaagccca 603  
 DB 703 ctgaaagaagagagagagagcttggagttgcaacagttcagcggagactgaagccca 762  
 QY 604 gaggaatacagagcaaaagagagaagagcagagcgttggagattgctcgtatga 663  
 DB 763 gaggaatacagagcaaaagagagaagagcagagcgttggagattgctcgtatga 822  
 QY 664 gtctctgtacttctgttctccagtggttccattctctctctctctgtgacata 723  
 DB 823 gtctctgtacttctgttctccagtggttccattctctctctctctgtgacata 882  
 QY 724 tatgcttaataagcagatgcttgcctgcctcgcgaataagagagatatacc 783  
 DB 883 tatgcttaataagcagatgcttgcctgcctcgcgaataagagagatatacc 942  
 QY 784 caggtacatacagtaacgcgcgcagcaagattgactatgtgttccagcttaaggtg 843  
 DB 943 caggtacatacagtaacgcgcgcagcaagattgactatgtgttccagcttaaggtg 1002  
 QY 844 ttgtgttttctgttctgtatgttctgttataaaaaaataagaaa 894

DB 1003 ttgtgttttctgttctgtatgttctgttataaaaaaataagaaa 1053

RESULT 3

AAS62602/c  
 ID AAS62602 standard; cDNA; 891 BP.

AC AAS62602;

DT 14-FEB-2002 (first entry)

DE cDNA sequence #389 encoding novel human secreted protein.

XX Human secreted protein; hyperproliferative disorder; autoimmune disorder;

KW Immune deficiency disorder; blood disorder; inflammatory disorder;

KW Infectious disorder; gene therapy; antimicrobial; hepatotropic;

OS Homo sapiens.

PN MO200177291-A2.

PD 18-OCT-2001.

PF 29-MAR-2001; 2001WO-US10485.

PR 06-APR-2000; 2000US-195604P.

PA (GENEY ) GENETICS INST INC.

PI Wong GC, Clark HF, Fehel K, Agostino MJ, Howes SH, Resnick RJ;

PI Gulukota K, Graham JR;

DR WPI: 2002-010900/01.

XX New polynucleotides encoding secreted proteins useful for treating e.g.

PT asthma, HIV and Crohn's disease -

PS Claim 1; Page 280; 391pp; English.

CC The present invention relates to the isolation of novel cDNA sequences  
 CC which encode human secreted proteins. The cDNA sequences have been  
 CC derived from a variety of human tissues. The invention also provides  
 CC a method for producing proteins from these polynucleotide sequences.  
 CC The proteins are useful for identifying compounds that modulate their  
 CC activity and production, and the cell is also useful for identifying  
 CC compounds that modulate expression of the polynucleotide sequences  
 CC encoding the secreted proteins. The sequences of the invention are  
 CC useful for treating diseases such as hyperproliferative disorders  
 CC (e.g. cancer), immune deficiency disorders (e.g. severe combined  
 CC immunodeficiency (SCID)), autoimmune disorders (e.g. multiple  
 CC sclerosis), blood disorders (e.g. thrombocytopenia), inflammatory  
 CC disorders (e.g. arthritis) and infectious disorders (e.g. hepatitis).  
 CC The polynucleotide sequences of the invention are also useful in gene  
 CC therapy. AAS62214-AAS62838 represent the cDNA sequences of the  
 CC invention that encode for novel human secreted proteins.

SO Sequence 891 BP; 221 A; 224 C; 157 G; 289 T; 0 other;

Query Match 97.2%; Score 869.4; DB 24; Length 891;  
 Best Local Similarity 99.8%; Pred. No. 2.7e-223;  
 Matches 881; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 13 aggggttaacaagatgagcagcagagcgttgagagctccataagcttaagcttgcgaacta 72  
 DB 886 AAGGCTAACCAAGATGGCCAGCCAGCGGTGAGCTCCATAACCTTAACCTTCCCAACTA 827  
 QY 73 aagcaagaatgctgtcgtcgtgtgtgttgagaccaagaggaataaagcaagatctacac 132  
 DB 826 AAGCAAGATGCTGTCTGCTGTGTGTGTGAGACCAAGGAGATTAAGCAAGATCTTATCCAC 767

```
QY 133 agactccaggcatatcttgaagaacatgctgaagaaggagcaaaatgaagaatgtactg 192
DB 766 AGACTCCAGGCAATCTTTGAAGAACATGCTGAAGAGGAGCAAAATGAAGAGATGTACTG 707
QY 193 ggaataaacaagaggaagaagaacaaagccattgagccctctgtcaagaaggaagaa 252
DB 706 GGAATGAACAGAGAGAGAGAAACAAAGCCATTGAGCTCCCTGCTGCTGAAGAGAGAA 647
QY 253 ccccttgaaaaaactgttgaatgtgcagcaagaagaagatggtgaataatcatctga 312
DB 646 CCCCCTGAAAAAACTGTTGATGTGGCAGCAGACAGAGAAAGAGTGGAATTAATCATCTTAA 587
QY 313 ataccacagactgagagaatgcaagaaggctgaacgatccaatgtacatctgtgacttg 372
DB 586 ATACCACAGACTGAGAGAAATGCAGAGAGGAGGCTGAACATTCATATGTAATGTAAGCTTG 527
QY 373 gagggtagaagaagctgtctgcgcagcagctaggttttgagattcttcaagttccaaagaag 432
DB 526 GAGAGTAAGAAAGCTGCTGGGAGCTAGAGTTTGCGATTCTTCAAGTCCAAACAAAAGGT 467
QY 433 ctgtcatctgaataacaacctatggttaacttgataagctgaagaagaaggctcaaga 492
DB 466 CTGTCACTGATTAACAACCAATGATGTTAACTTGATTAAGCTGAAGAGAAAGCTCAAGA 407
QY 493 ttgtgttgaatgtctcttcaatctcagaagaagctgaagaatgaatgaagaatgaagaag 552
DB 406 TTTGTTTGAATGCTCTTCAATCTCCAGAAAGTCTGAAGATGATGAAGAACTGAAAAAG 347
QY 553 aggaagaagcagatttgagatgttcacaagttcaagctggaac-tgaaccaagaaggatcac 611
DB 346 AGGAAGAAGCGATTGGATTGGATTGTCAAGATTCAGCTGGAACCTTGGAACACAGAGATAC 287
QY 612 agaagcaagaagaagaagaagcagagcagcttggagattcccgatgaagaagttccctga 671
DB 286 AGAGCAAGAAGAGAGAGAAAGAGAGAGCGCTTTGGATTCCCTGATGAAGAAAGTTCCGA 227
QY 672 taacttctgtctcagatgtttccatcttctcctcttcttcttctgtgcaatataatgctca 731
DB 226 TACTTCTGTCTCTCCATGTTTCCATTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 167
QY 732 aatgcacaagcatgtgctcagctcgtcctcgcgaatgaggaagatgtaaccccggtaca 791
DB 166 AATGCACAAGTCATGTGCTTACGTCTGCTCGCAATGAGGAGCATGACCCCAAGTACA 107
QY 792 tccatgacagcgcgcagcaagatttgactatgtcgtttcaagcttaagatgtgtgttt 851
DB 106 TCCATGAACTGCGGACAGAGTTTACTTATGTGCTTTCAGCTTTAAGGTTGTGTGTT 47
QY 852 ttgttttgattatgtctgttgaataaaaaaataagaana 894
DB 46 TTTGTTTGAATTAATGTTGCTGTTAATTAATAAATAATAGAAAA 4
RESULT 4
AAC00738
ID AAC00738 standard; cDNA; 471 BP.
XX AAC00738;
AC
XX
XX 06-OCT-2000 (first entry)
DE Human secreted protein 5' EST, SEQ ID NO: 736.
XX
XX Human: 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KM gene therapy; chromosome mapping; ss.
XX
XX Homo sapiens.
XX EP1033401-A2.
XX PN
XX 06-SEP-2000.
XX
XX 21-FEB-2000; 2000EP-0200610.
PF
```

```
XX
PR 26-FEB-1999; 99US-0122487.
XX
XX (GEST ) GENSET.
PA
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
XX WPI: 2000-500381/45.
DR P-PSDB; AAG00732.
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures -
PS Claim 1; SEQ ID 736; 71pp + CD-ROM; English.
XX
CC The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. An ORF has been identified within the
CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
CC derived from 30 different tissues. EST sequences usually correspond
CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC well suited for isolating cDNA sequences derived from the 5' ends of
CC mRNAs and even in those cases where longer cDNA sequences have been
CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
CC mRNAs with intact 5' ends and can therefore be used to obtain full length
CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
CC gene therapy and chromosome mapping procedures. They are used to obtain
CC upstream regulatory sequences and to design expression and secretion
CC vectors.
SQ Sequence 471 BP; 165 A; 81 C; 130 G; 94 T; 1 other;
```

```
Query Match 52.3%; Score 467.6; DB 21; Length 471;
Best Local Similarity 99.8%; Pred. No. 1.3e-115;
Matches 467; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 4 agtgaagtgagggggaagaagatggcgacgcagagcgggagggagctccataagctaaagctt 63
DB 4 agtgaagtgagggggaagaagaatggcgacgcagagcgggagggagctccataagctaaagctt 63
QY 64 gccgaactaaagcaagaatgtctgtctgtgttggagacaaaggaataaagcaaat 123
DB 64 gccgaactaaagcaagaatgtctgtctgtgttggagacaaaggaataaagcaaat 123
QY 124 ctatccacagactccagatcatcttgaagaacatgctgaagaaggaggaatagaaga 183
DB 124 ctatccacagactccagatcatcttgaagaacatgctgaagaaggaggaatagaaga 183
QY 184 gatgtactggagatgtgaacagaggaagaagaacaaagccattgaagctccctgtcaaa 243
DB 184 gatgtactggagatgtgaacagaggaagaagaacaaagccattgaagctccctgtcaaa 243
QY 244 gaggaagaagcccttgaaaaaactgttgaatgtgcagcagagagaagaagaatgtgaanaat 303
DB 244 gaggaagaagcccttgaaaaaactgttgaatgtgcagcagagagaagaagaatgtgaanaat 303
QY 304 acatctgaataccaacagactgagagaatgcaagaaggagctgaagaatgaatgtacct 363
DB 304 acatctgaataccaacagactgagagaatgcaagaaggagctgaagaatgaatgtacct 363
QY 364 gtgagcttgagagatgaagaagctgtctggcagcagctaaagtgttgattcttgcttca 423
DB 364 gtgagcttgagagatgaagaagctgtctggcagcagctaaagtgttgattcttgcttca 423
QY 424 acaaaaggtctcatctgaatacaaacctatgtgttaactgtgataag 471
DB 424 acaaaaggtctcatctgaatacaaacctatgtgttaactgtgataag 471
```

```
RESULT 5
AAH81555
```

ID	AAH81555 standard; DNA; 408 BP.
XX	
AC	AAH81555;
XX	
DT	21-SEP-2001 (first entry)
XX	
DE	Human differential transcription-associated cDNA SEQ ID 64.
XX	
KW	Differential transcription; human; rat; tumour cell; cytostatic;
KW	Ras modulator; Class II tumour suppressor gene; gene therapy; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200157058-A2.
XX	
PD	09-AUG-2001.
PF	
PI	31-JAN-2001; 2001WO-EP01003.
PR	31-JAN-2000; 2000DE-1004102.
PA	(META-) METAGEN GES GENOMFORSCHUNG MBH.
PI	Rosenthal A, Hinzmann B, Schaefer R, Zuber J, Tchernitsa O;
PI	Grips M, Hellriegel M, Schmitz A, Sers C;
DR	WPI: 2001-483415/52.
PT	Nucleic acids differentially expressed between tumor and normal cells,
PT	useful for diagnosis or therapy of tumors and for screening active
PS	agents -
XX	
PS	Disclosure; Page 350; 579pp; German.
CC	
CC	This invention describes a nucleic acid (I) with differential expression
CC	between tumour and normal cells and which has cytoskeletal activity. (I)
CC	work as modulators of Ras activity by inducing expression of tumour
CC	suppressor genes. (I), and polypeptides encoded by them, are useful as
CC	targets for diagnosis or therapy and in screening to determine the
CC	effects of an active compound (potential pharmaceutical) on a cell line,
CC	particularly for diagnosis and treatment of tumors, especially by
CC	modulating expression of (I) (by gene therapy, antisense RNA or ribozyme
CC	methods) or by modulating the amount and/or location of (I)-encoded
CC	polypeptides (by administration of the polypeptide or its activator,
CC	antibody (optionally as a conjugate) or inhibitor). The method allows
CC	identification of many Class II tumour suppressor genes (i.e. genes that
CC	are not primary targets for tumour-initiating mutations).
CC	AAH81492-AAH8376 represent the human and rat derived nucleic acid
CC	fragments described in the method of the invention.
XX	
SQ	Sequence 408 BP; 141 A; 66 C; 111 G; 88 T; 2 other;
	Query Match            37.4%; Score 334; DB 22; Length 408;
	Best Local Similarity   98.0%; Pred. No. 9e-80; Indels     6; Gaps       6
	Matches   400; Conservative   0; Mismatches   2; Indels     6; Gaps       6
OY	190 ctggagatgataaacacagagaagaagaacaagccattgaagtccctgtcaagaaggaa 249
DB	1 ctggagatgataaacacagagaagaagaacaagccattgaagtccctgtcaagaaggaa 60
OY	250 gaacccccctgaaaaaactgttgatgtgtagcagaagaagaagtgtgtaaatcaatct 309
DB	61 gaacccccctgaaaaaactgttgatgtgtagcagaagaagaagtgtgtaaatcaatct 120
OY	310 gaataaccacaactgagagaaatgcagaagaaggctgaaacgattcaatgtacctgtgac 369
DB	121 gaaatacccacgactcgaggaatgcagaagaaggctgaaacgattcaatgtacctgtgac 180
OY	370 ttggagagttaagaaaagctgctcgggcagctaggtttggattcttcagttccaacaaaa 429
DB	181 ttggagagttaagaaaagctgctcgggcagctaggtttggattcttcagttccaacaaaa 240

QY	430	ggctgtgcattcgtataacaactatggttaactt- 	ggataagctggaaggaaagct-c	487
Db	241	ggctgtgcattcgtataacaactatggttaactt- 	ggataagctggaaggaaagctcc	300
QY	488	aaaatttggtttggaagctcttcacatccagaagtc- 	tgaagatgatga-gaaact	545
Db	301	aaaatttggtttggaagctcttcacatccagaagctt- 	ggaatgatgatgagagaaact	360
QY	546	gaaaaga-ggaaggagcattt- 	gggattgtcacaaagttcagctgga	591
Db	361	gaaaagaaggaagcagcatttgggagattgtcacaa- 	ggttcagctcagctgga	408
RESULT 6				
AAL37635/c				
ID	AAL37635 standard; DNA: 5469 BP.			
XX	AAL37635;			
XX	08-JAN-2002 (first entry)			
De	Human musculoskeletal system related polynucleotide SEQ ID NO 4000.			
KW	Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;			
KW	antiallergic; hepatotoxic; antidiabetic; antinflammatory; antiulcer;			
KW	vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;			
KW	cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;			
KW	neurological disease; infection; human; secreted protein;			
KW	musculoskeletal system; ds.			
XX	Homo sapiens.			
OS	Wo200155367-A1.			
PN	Wo200155367-A1.			
XX	02-AUG-2001.			
PD	17-JAN-2001; 2001WO-US01338.			
XX	31-JAN-2000;	2000US-0179065-		
PR	04-FEB-2000;	2000US-0180628-		
PR	24-FEB-2000;	2000US-0184664-		
PR	02-MAR-2000;	2000US-0186350-		
PR	16-MAR-2000;	2000US-0189874-		
PR	17-MAR-2000;	2000US-0190076-		
PR	18-APR-2000;	2000US-0198123-		
PR	19-MAY-2000;	2000US-0205515-		
PR	07-JUN-2000;	2000US-0209467-		
PR	28-JUN-2000;	2000US-0214886-		
PR	30-JUN-2000;	2000US-0215135-		
PR	07-JUL-2000;	2000US-0216647-		
PR	07-JUL-2000;	2000US-0216880-		
PR	11-JUL-2000;	2000US-0217487-		
PR	14-JUL-2000;	2000US-0217496-		
PR	14-JUL-2000;	2000US-0218290-		
PR	26-JUL-2000;	2000US-0220963-		
PR	26-JUL-2000;	2000US-0220964-		
PR	14-AUG-2000;	2000US-0224518-		
PR	14-AUG-2000;	2000US-0224519-		
PR	14-AUG-2000;	2000US-0224513-		
PR	14-AUG-2000;	2000US-0225214-		
PR	14-AUG-2000;	2000US-0225266-		
PR	14-AUG-2000;	2000US-0225267-		
PR	14-AUG-2000;	2000US-0225268-		
PR	14-AUG-2000;	2000US-0225270-		
PR	14-AUG-2000;	2000US-0225447-		
PR	14-AUG-2000;	2000US-0225757-		
PR	14-AUG-2000;	2000US-0225758-		
PR	14-AUG-2000;	2000US-0225759-		
PR	18-AUG-2000;	2000US-0226279-		
PR	22-AUG-2000;	2000US-0226681-		
PR	22-AUG-2000;	2000US-0226682-		
PR	22-AUG-2000;	2000US-0227182-		
PR	23-AUG-2000;	2000US-0227009-		



Oy	672	tactttctgttctccagtggttttccaattcttcctctcttcttggttaacataatgtgcta	731
Db	4905	TACTTCTCTCTTCCGAGGTTCATTTCTCTCTTCTTCTTGTCACATATATGGCTA	4846
Oy	732	aatgcacagtcagtgtccctacagtcctcgccctgaatgaggagcatgtacccaggtaca	791
Db	4845	AATGCACATCATGTCTCCCTACGTCTCTGCTCCGCAATGAGGAGCATGTACCCAGGTACA	4786
Oy	792	lccatgaactctgcgcagcagcagtttgacttaltgctgtgttcagcttaaggtgtgtgtt	851
Db	4785	TCCATGAATCGCGGAGAGATTGTGACTTATTTGCTGTTCAGCTTAAAGTTGTGTGT	4726
Oy	852	ttgttttgattatgtgtgtgtgttaataaaaaaataagaaaa	894
Db	4725	TTGTTTTGTATTATGTTGCTGTTAATAAAAAAATAAGAAA	4683
RESULT 7			
ID	ABA08022/c		
XX	ABA08022 standard; DNA; 5469 BP.		
AC	ABA08022;		
XX			
DT	11-JAN-2002 (first entry)		
XX			
DE	Human ovarian and breast cancer associated polynucleotide SEQ ID NO 817.		
XX			
KM	Cytostatic; immunosuppressive; nootropic; neuroprotective; antifolal;		
KM	antiallergic; hepatotropic; antidiabetic; antiinflammatory; anticler;		
KM	vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;		
KM	cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;		
KM	neurological disease; infection; human; secreted protein; ds.		
XX			
OS	Homo sapiens.		
PN			
XX	WO200155325-A2.		
PD			
XX	02-AUG-2001.		
PF			
XX	17-JAN-2001; 2001WO-US01345.		
PR	31-JAN-2000; 2000US-0179065.		
PR	04-FEB-2000; 2000US-0180628.		
PR	24-FEB-2000; 2000US-0184664.		
PR	02-MAR-2000; 2000US-0186350.		
PR	16-MAR-2000; 2000US-0189874.		
PR	17-MAR-2000; 2000US-0190076.		
PR	18-APR-2000; 2000US-0198123.		
PR	19-MAY-2000; 2000US-0205153.		
PR	07-JUN-2000; 2000US-0209467.		
PR	28-JUN-2000; 2000US-0214886.		
PR	30-JUN-2000; 2000US-0215135.		
PR	07-JUL-2000; 2000US-0216647.		
PR	11-JUL-2000; 2000US-0217487.		
PR	11-JUL-2000; 2000US-0217496.		
PR	14-JUL-2000; 2000US-0218290.		
PR	26-JUL-2000; 2000US-0220963.		
PR	26-JUL-2000; 2000US-0220964.		
PR	14-AUG-2000; 2000US-0224518.		
PR	14-AUG-2000; 2000US-0224519.		
PR	14-AUG-2000; 2000US-0225213.		
PR	14-AUG-2000; 2000US-0225214.		
PR	14-AUG-2000; 2000US-0225266.		
PR	14-AUG-2000; 2000US-0225267.		
PR	14-AUG-2000; 2000US-0225268.		
PR	14-AUG-2000; 2000US-0225270.		
PR	14-AUG-2000; 2000US-0225447.		
PR	14-AUG-2000; 2000US-0225757.		
PR	14-AUG-2000; 2000US-0225758.		
PR	14-AUG-2000; 2000US-0225759.		
PR	18-AUG-2000; 2000US-0226279.		
PR	22-AUG-2000; 2000US-0226681.		

PR	22-AUG-2000	2000US-0226666
PR	22-AUG-2000	2000US-0227182
PR	23-ANG-2000	2000US-0227709
PR	30-ANG-2000	2000US-0228924
PR	01-SEP-2000	2000US-0229287
PR	01-SEP-2000	2000US-0229343
PR	01-SEP-2000	2000US-0229344
PR	01-SEP-2000	2000US-0229345
PR	05-SEP-2000	2000US-0229509
PR	05-SEP-2000	2000US-0229513
PR	06-SEP-2000	2000US-0230437
PR	06-SEP-2000	2000US-0230438
PR	08-SEP-2000	2000US-0231242
PR	08-SEP-2000	2000US-0231243
PR	08-SEP-2000	2000US-0231244
PR	08-SEP-2000	2000US-0231114
PR	08-SEP-2000	2000US-0231113
PR	08-SEP-2000	2000US-0232081
PR	08-SEP-2000	2000US-0232080
PR	12-SEP-2000	2000US-0231968
PR	14-SEP-2000	2000US-0232397
PR	14-SEP-2000	2000US-0232398
PR	14-SEP-2000	2000US-0232399
PR	14-SEP-2000	2000US-0232400
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0233063
PR	14-SEP-2000	2000US-0233064
PR	26-SEP-2000	2000US-0234598
PR	26-SEP-2000	2000US-0235484
PR	27-SEP-2000	2000US-0235834
PR	27-SEP-2000	2000US-0235836
PR	29-SEP-2000	2000US-0236527
PR	29-SEP-2000	2000US-0236527
PR	29-SEP-2000	2000US-0236569
PR	29-SEP-2000	2000US-0236568
PR	29-SEP-2000	2000US-0236670
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237039
PR	02-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239353
PR	13-OCT-2000	2000US-0239357
PR	20-OCT-2000	2000US-0240960
PR	20-OCT-2000	2000US-0241121
PR	20-OCT-2000	2000US-0241186
PR	20-OCT-2000	2000US-0241185
PR	20-OCT-2000	2000US-0241877
PR	20-OCT-2000	2000US-0241808
PR	20-OCT-2000	2000US-0241809
PR	20-OCT-2000	2000US-0246527
PR	01-NOV-2000	2000US-0246117
PR	01-NOV-2000	2000US-0246118
PR	08-NOV-2000	2000US-0246474
PR	08-NOV-2000	2000US-0246475
PR	08-NOV-2000	2000US-0246476
PR	08-NOV-2000	2000US-0246477
PR	08-NOV-2000	2000US-0246478
PR	08-NOV-2000	2000US-0246523
PR	08-NOV-2000	2000US-0246524
PR	08-NOV-2000	2000US-0246525
PR	08-NOV-2000	2000US-0246526
PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246528
PR	08-NOV-2000	2000US-0246529
PR	08-NOV-2000	2000US-0246609
PR	08-NOV-2000	2000US-0246611
PR	08-NOV-2000	2000US-0246611
PR	17-NOV-2000	2000US-0249207



PR 17-NOV-2000; 2000US-0249308.  
 PR 17-NOV-2000; 2000US-0249209.  
 PR 17-NOV-2000; 2000US-0249210.  
 PR 17-NOV-2000; 2000US-0249211.  
 PR 17-NOV-2000; 2000US-0249212.  
 PR 17-NOV-2000; 2000US-0249213.  
 PR 17-NOV-2000; 2000US-0249214.  
 PR 17-NOV-2000; 2000US-0249215.  
 PR 17-NOV-2000; 2000US-0249216.  
 PR 17-NOV-2000; 2000US-0249217.  
 PR 17-NOV-2000; 2000US-0249218.  
 PR 17-NOV-2000; 2000US-0249244.  
 PR 17-NOV-2000; 2000US-0249245.  
 PR 17-NOV-2000; 2000US-0249264.  
 PR 17-NOV-2000; 2000US-0249265.  
 PR 17-NOV-2000; 2000US-0249297.  
 PR 17-NOV-2000; 2000US-0249299.  
 PR 17-NOV-2000; 2000US-0249300.  
 PR 01-DEC-2000; 2000US-0250160.  
 PR 01-DEC-2000; 2000US-0250391.  
 PR 05-DEC-2000; 2000US-0251030.  
 PR 05-DEC-2000; 2000US-0251088.  
 PR 05-DEC-2000; 2000US-0251679.  
 PR 06-DEC-2000; 2000US-0251679.  
 PR 08-DEC-2000; 2000US-0251856.  
 PR 08-DEC-2000; 2000US-0251868.  
 PR 08-DEC-2000; 2000US-0251869.  
 PR 08-DEC-2000; 2000US-0251899.  
 PR 08-DEC-2000; 2000US-0251900.  
 PR 11-DEC-2000; 2000US-0254097.  
 PR 05-JAN-2001; 2001US-0259678.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 PI Rosen CA, Barash SC, Ruben SM;  
 XX  
 DR WPI: 2001-488786/53.  
 XX  
 PT New isolated ovarian and/or breast cancer related nucleic acids and  
 PT polypeptides, useful for diagnosing, treating and/or preventing human  
 PT diseases and disorders, particularly ovarian and/or breast cancer -  
 XX  
 PS  
 PS Disclosure; SEQ ID NO 817; 577pp + Sequence Listing; English.  
 XX  
 CC The invention relates to novel genes (ABA07454-ABA08224) and proteins  
 CC (ABAI0743-ABAI0980) useful for preventing, treating or ameliorating  
 CC medical conditions e.g. by protein or gene therapy. The genes are  
 CC isolated from a range of human tissues disclosed in the specification  
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful  
 CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast  
 CC and ovarian cancer and other cancers of the adrenal gland, bone, bone  
 CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;  
 CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune  
 CC hemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's  
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative  
 CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;  
 CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and  
 CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal  
 CC and parasitic infections.  
 CC Note: The sequence data for this patent did not form part of the  
 CC printed specification, but was obtained in electronic format directly  
 CC from WIPO at ftp.wipo.int/pub/published\_pcl\_sequences.  
 XX  
 XX Sequence 5469 BP; 1793 A; 1119 C; 1201 G; 1356 T; 0 other;

Query Match	31.5%	Score 281.4;	DB 22;	Length 5469;
Best Local Similarity	99.6%;	Pred. No. 3.6e-65;		
Matches 282; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

QY 612 agagggcaaaagaagaaaagcagagcgcttltggtatgcctgatgaagtccctga 671  
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 4965 ACACGCCAAAGCAGCGAAAAGCAGCAGCGCTTTGGCATTTGCTGTATCAAAACTTCCCTGA 4906

OY	672	tactttctgtcttccaaatggttttccattcttcctctcttctgtgtcaataatagccta	731
Db	4905	TACTTTCTGTCTTCCAAATGGTTTTCCATTTTCTCTCTCTCTCTGGTGCACATATATGCCCA	4846
OY	732	aatcacagatcatgttgctactcgttcctgcgcgaatgaagagacatgtaccacagttaca	791
Db	4845	AATGCACAGTCATATGCTGCTTACGTCTCTGCTCGCAATGAGGAGCATTGACCCAGGTACA	4786
OY	792	tccatgaactctgcgcacagatttgacttaattgtctgttccacgttlaagtttgtgttt	851
Db	4785	TCCATGAACCTCGGCACAGATTGACATTATTTGCTTGCTTACGCTTTAAGTGTGTGTGT	4722
OY	852	ttgttttttgaatagtgtgcttgttaataaaaaaaaaataagaaaa	894
Db	4725	TTGTTTGTGATTGTTGCTGTGTTAAATAAAAAAATAGAAAA	4683

RESULT	8
AA106683/C	
ID	AA106683 standard; DNA; 5469 BP.
XX	
AC	AA106683;
XX	
DT	21-NOV-2001 (first entry)

Human reproductive system related antigen DNA SEQ ID NO: 9371.

KW Human; reproductive system related antigen; reproductive system disorder  
KW cancer; gene therapy; ds.

OS Homo sapiens

PN W0200155320-A2

02-ATIG-2001

17-JAN-2001; 2001WO-US01339.

XX  
PR 31-JAN-2000: 2000US-0179065

PR 04-FEB-2000; 2000US-0180628.  
 04 FEB 2000 0184554

PR 02-MAR-2000; 2000US-0186350

17-MAR-2000; 2000US-0190076.

PR 18-APR-2000; 2000US-0198123  
PR 19-MAY-2000; 2000US-0205515

PR 07-JUN-2000; 2000US-0209467;  
 08-JUN-2000; 2000US-0214885

PR 30-JUN-2000; 2000US-0215135

07-JUL-2000; 2000US-0216880.

11-JUL-2000; 2000UTS-0217496  
PR  
PR

PR 14-JUL-2000; 2000US-0218290  
PR 26-JUL-2000; 2000US-0230953

PR 26-JUL-2000; 2000US-0220964

PR 14-AUG-2000; 2000US-0224519

PR 14-AUG-2000; 2000HS-0225214

PR 14-AUG-2000; 2000US-0225266  
PR 14-AUG-2000; 2000US-0225267

PR 14-AUG-2000; 2000US-0225268

PR 14-AUG-2000; 2000US-0225447

PR 14-AUG-2000; 2000TTS-0225758

PR 14-AUG-2000; 2000US-0225759  
 PR 19-AUG-2000; 2000US-0225770

PR 22-AUG-2000; 2000US-0226681

PR 22-AUG-2000; 2000US-0227182



```
RESULT      9
AAK84119/c
ID AAK84119 standard; DNA: 5469 BP.
XX
AC AAK84119;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:38931.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
```

```
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0234998.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235835.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0238935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246611.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
```



```

PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 25-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.

```

```

PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0251990.
PR 05-JAN-2001; 2001US-0259678.
XX (HUMA-) HUMAN GENOME SCI INC.
PA Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-451937/48.
XX WPI; 2001-451937/48.
DR Isolated polypeptide for treating, preventing and/or prognosing
XX disorders related to the musculoskeletal system including
XX musculoskeletal cancers and also for testing and detection e.g.
XX diagnosis -
XX Example 2; SEQ ID NO 3999; 781bp + Sequence Listing: English.
XX
XX The invention relates to novel genes (AAL34669-AAL37666) and proteins
XX (ABB03087-ABB04109) associated with the musculoskeletal system useful
XX for preventing, treating or ameliorating medical conditions e.g. by
XX protein or gene therapy. The genes are isolated from a range of human
XX tissues disclosed in the specification. The nucleic acids, proteins,
XX antibodies and (ant)agonists are useful in the diagnosis, treatment
XX and prevention of: (a) cancer, e.g. breast and ovarian cancer and
XX gastrointestinal tract, liver, lung, or urogenital; (b) immune
XX disorders e.g. Addison's disease, allergies, autoimmune haemolytic
XX anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
XX multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
XX (c) cardiovascular disorders such as myocardial ischaemia; (d) wound
XX healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy;
XX and (f) infectious diseases such as viral, bacterial, fungal and
XX parasitic infections.
XX Note: The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 9453 BP; 2869 A; 2071 C; 2294 G; 2219 T; 0 other;
SO
Query Match 31.5%; Score 281.4; DB 22; Length 9453;
Best Local Similarity 99.6%; Pred. No. 4,56-65;
Matches 282; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 612 agaggcaagaagaggaagaagagcagcgttggaggttgcctgcatataaagtccga 671
DB 8949 ACAGGCAAGAAGAGGAAGAGAGGAGCGCTTGGGATTCGCTATATAAAGTCCGGA 8890
OY 672 tacttcgtctccaggttttccattctctcccttcttcttcttgcacataatagccta 731
DB 8889 TACTTTCGTTCTCCAGGTGTTTCCATTTCCTCTTCTTCTGTCACATATAGCCTA 8830
OY 732 aatgcacagtcattgtcctaagctcgtcctcgaatgagggagcaatgtaaccagta 791
DB 8829 AATGCACAGTCATGTGCTTACGTCTCGCTGCAATGAGGAGCATACCCAGGTACA 8770
OY 792 tccatgaactgcgagcaagtttgaactatgctgttcaacttaaggttgttgtt 851
DB 8769 TCATGAACCTGCGGCGCAGGTTTGACTTATGCTGTTCAGCTTAAAGGTGTGTTT 8710
OY 852 ttgttttgatattgtctgttataataaaaaataagaaa 894
DB 8710

```

DB 8709 TTGTTTTCATTATGTCCTGTTAATAAAAAAAAAAATACGAAA 8667  
RESULT 11  
ID ABA08021/c  
XX ABA08021 standard; DNA; 9453 BP.  
AC ABA08021;  
XX  
XX  
DF 11-JAN-2002 (first entry)  
XX  
DE Human ovarian and breast cancer associated polynucleotide SEQ ID NO 816.  
XX  
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;  
KM antiallergic; hepatotropic; antidiabetic; antiinflammatory; anticancer;  
KM vulnery; anticonvulsant; antibacterial; antifungal; antiparasitic;  
KM cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;  
KM neurological disease; infection; human; secreted protein; ds.  
XX  
OS Homo sapiens.  
XX  
PN W020015325-A2.  
XX  
PD 02-AUG-2001.  
XX  
XX 17-JAN-2001; 2001WO-US01345.  
XX  
PF 31-JAN-2000; 2000US-0179065.  
PR 04-FEB-2000; 2000US-0180628.  
PR 24-FEB-2000; 2000US-0184664.  
PR 02-MAR-2000; 2000US-0186350.  
PR 16-MAR-2000; 2000US-0189874.  
PR 17-MAR-2000; 2000US-0190706.  
PR 18-APR-2000; 2000US-0198123.  
PR 19-MAY-2000; 2000US-0205515.  
PR 07-JUN-2000; 2000US-0209467.  
PR 28-JUN-2000; 2000US-0214886.  
PR 30-JUN-2000; 2000US-0215135.  
PR 07-JUL-2000; 2000US-0216647.  
PR 07-JUL-2000; 2000US-0216880.  
PR 11-JUL-2000; 2000US-0217487.  
PR 11-JUL-2000; 2000US-0217496.  
PR 14-JUL-2000; 2000US-0218290.  
PR 26-JUL-2000; 2000US-0220963.  
PR 26-JUL-2000; 2000US-0220964.  
PR 14-AUG-2000; 2000US-0224518.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0225213.  
PR 14-AUG-2000; 2000US-0225214.  
PR 14-AUG-2000; 2000US-0225266.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225268.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 18-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226868.  
PR 22-AUG-2000; 2000US-0227182.  
PR 23-AUG-2000; 2000US-0227009.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 08-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.

PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.  
PR 14-SEP-2000; 2000US-0232401.  
PR 14-SEP-2000; 2000US-0232063.  
PR 14-SEP-2000; 2000US-0233064.  
PR 14-SEP-2000; 2000US-0233065.  
PR 21-SEP-2000; 2000US-0234223.  
PR 21-SEP-2000; 2000US-0234274.  
PR 25-SEP-2000; 2000US-0234997.  
PR 25-SEP-2000; 2000US-0234998.  
PR 25-SEP-2000; 2000US-0234999.  
PR 26-SEP-2000; 2000US-0235484.  
PR 27-SEP-2000; 2000US-0235834.  
PR 27-SEP-2000; 2000US-0235836.  
PR 27-SEP-2000; 2000US-0236327.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236368.  
PR 29-SEP-2000; 2000US-0236369.  
PR 29-SEP-2000; 2000US-0236370.  
PR 02-OCT-2000; 2000US-0236802.  
PR 02-OCT-2000; 2000US-0237037.  
PR 02-OCT-2000; 2000US-0237038.  
PR 02-OCT-2000; 2000US-0237039.  
PR 02-OCT-2000; 2000US-0237040.  
PR 13-OCT-2000; 2000US-02393935.  
PR 13-OCT-2000; 2000US-0239397.  
PR 20-OCT-2000; 2000US-0240960.  
PR 20-OCT-2000; 2000US-0241221.  
PR 20-OCT-2000; 2000US-0241785.  
PR 20-OCT-2000; 2000US-0241786.  
PR 20-OCT-2000; 2000US-0241787.  
PR 20-OCT-2000; 2000US-0241808.  
PR 20-OCT-2000; 2000US-0241809.  
PR 20-OCT-2000; 2000US-0241826.  
PR 01-NOV-2000; 2000US-0244617.  
PR 08-NOV-2000; 2000US-0246474.  
PR 08-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246476.  
PR 08-NOV-2000; 2000US-0246477.  
PR 08-NOV-2000; 2000US-0246478.  
PR 08-NOV-2000; 2000US-0246523.  
PR 08-NOV-2000; 2000US-0246524.  
PR 08-NOV-2000; 2000US-0246525.  
PR 08-NOV-2000; 2000US-0246526.  
PR 08-NOV-2000; 2000US-0246527.  
PR 08-NOV-2000; 2000US-0246528.  
PR 08-NOV-2000; 2000US-0246532.  
PR 08-NOV-2000; 2000US-0246609.  
PR 08-NOV-2000; 2000US-0246610.  
PR 08-NOV-2000; 2000US-0246611.  
PR 08-NOV-2000; 2000US-0246613.  
PR 17-NOV-2000; 2000US-0249207.  
PR 17-NOV-2000; 2000US-0249208.  
PR 17-NOV-2000; 2000US-0249209.  
PR 17-NOV-2000; 2000US-0249210.  
PR 17-NOV-2000; 2000US-0249211.  
PR 17-NOV-2000; 2000US-0249212.  
PR 17-NOV-2000; 2000US-0249213.  
PR 17-NOV-2000; 2000US-0249214.  
PR 17-NOV-2000; 2000US-0249215.  
PR 17-NOV-2000; 2000US-0249216.  
PR 17-NOV-2000; 2000US-0249217.  
PR 17-NOV-2000; 2000US-0249218.  
PR 17-NOV-2000; 2000US-0249244.  
PR 17-NOV-2000; 2000US-0249245.  
PR 17-NOV-2000; 2000US-0249264.







XX Homo sapiens.  
OS  
XX  
PN WO200157182-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 17-JAN-2001; 2001WO-US01354.  
XX  
PR 31-JAN-2000; 2000US-0179065.  
PR 04-FEB-2000; 2000US-0180628.  
PR 24-FEB-2000; 2000US-0184664.  
PR 02-MAR-2000; 2000US-0186350.  
PR 16-MAR-2000; 2000US-0189874.  
PR 17-MAR-2000; 2000US-0190076.  
PR 18-APR-2000; 2000US-0198123.  
PR 19-MAY-2000; 2000US-0205515.  
PR 07-JUN-2000; 2000US-0209467.  
PR 28-JUN-2000; 2000US-0214886.  
PR 30-JUN-2000; 2000US-0215135.  
PR 07-JUL-2000; 2000US-0216647.  
PR 07-JUL-2000; 2000US-0216880.  
PR 11-JUL-2000; 2000US-0217487.  
PR 11-JUL-2000; 2000US-0217496.  
PR 14-JUL-2000; 2000US-0218290.  
PR 26-JUL-2000; 2000US-0220963.  
PR 26-JUL-2000; 2000US-0220964.  
PR 14-AUG-2000; 2000US-0224518.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0225213.  
PR 14-AUG-2000; 2000US-0225214.  
PR 14-AUG-2000; 2000US-0225266.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225258.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 18-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226868.  
PR 22-AUG-2000; 2000US-0227182.  
PR 23-AUG-2000; 2000US-0227109.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 08-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.  
PR 14-SEP-2000; 2000US-0232401.  
PR 14-SEP-2000; 2000US-0233063.  
PR 14-SEP-2000; 2000US-0233064.  
PR 14-SEP-2000; 2000US-0233065.  
PR 21-SEP-2000; 2000US-0234223.  
PR 21-SEP-2000; 2000US-0234274.  
PR 25-SEP-2000; 2000US-0234997.  
PR 25-SEP-2000; 2000US-0234998.

PR 26-SEP-2000; 2000US-0235484.  
PR 27-SEP-2000; 2000US-0235834.  
PR 27-SEP-2000; 2000US-0235836.  
PR 29-SEP-2000; 2000US-0236327.  
PR 29-SEP-2000; 2000US-0236367.  
PR 29-SEP-2000; 2000US-0236368.  
PR 29-SEP-2000; 2000US-0236369.  
PR 29-SEP-2000; 2000US-0236370.  
PR 02-OCT-2000; 2000US-0236802.  
PR 02-OCT-2000; 2000US-0237037.  
PR 02-OCT-2000; 2000US-0237038.  
PR 02-OCT-2000; 2000US-0237039.  
PR 02-OCT-2000; 2000US-0237040.  
PR 13-OCT-2000; 2000US-0239935.  
PR 13-OCT-2000; 2000US-0239937.  
PR 20-OCT-2000; 2000US-0240960.  
PR 20-OCT-2000; 2000US-0241221.  
PR 20-OCT-2000; 2000US-0241785.  
PR 20-OCT-2000; 2000US-0241786.  
PR 20-OCT-2000; 2000US-0241787.  
PR 20-OCT-2000; 2000US-0241808.  
PR 20-OCT-2000; 2000US-0241809.  
PR 20-OCT-2000; 2000US-0241826.  
PR 01-NOV-2000; 2000US-0244617.  
PR 08-NOV-2000; 2000US-0246474.  
PR 08-NOV-2000; 2000US-0246475.  
PR 08-NOV-2000; 2000US-0246476.  
PR 08-NOV-2000; 2000US-0246477.  
PR 08-NOV-2000; 2000US-0246478.  
PR 08-NOV-2000; 2000US-0246523.  
PR 08-NOV-2000; 2000US-0246524.  
PR 08-NOV-2000; 2000US-0246525.  
PR 08-NOV-2000; 2000US-0246526.  
PR 08-NOV-2000; 2000US-0246527.  
PR 08-NOV-2000; 2000US-0246528.  
PR 08-NOV-2000; 2000US-0246532.  
PR 08-NOV-2000; 2000US-0246609.  
PR 08-NOV-2000; 2000US-0246610.  
PR 08-NOV-2000; 2000US-0246611.  
PR 08-NOV-2000; 2000US-0246613.  
PR 17-NOV-2000; 2000US-0249207.  
PR 17-NOV-2000; 2000US-0249208.  
PR 17-NOV-2000; 2000US-0249209.  
PR 17-NOV-2000; 2000US-0249210.  
PR 17-NOV-2000; 2000US-0249211.  
PR 17-NOV-2000; 2000US-0249212.  
PR 17-NOV-2000; 2000US-0249213.  
PR 17-NOV-2000; 2000US-0249214.  
PR 17-NOV-2000; 2000US-0249215.  
PR 17-NOV-2000; 2000US-0249216.  
PR 17-NOV-2000; 2000US-0249217.  
PR 17-NOV-2000; 2000US-0249218.  
PR 17-NOV-2000; 2000US-0249244.  
PR 17-NOV-2000; 2000US-0249245.  
PR 17-NOV-2000; 2000US-0249264.  
PR 17-NOV-2000; 2000US-0249265.  
PR 17-NOV-2000; 2000US-0249297.  
PR 17-NOV-2000; 2000US-0249299.  
PR 17-NOV-2000; 2000US-0249300.  
PR 01-DEC-2000; 2000US-0250160.  
PR 01-DEC-2000; 2000US-0250391.  
PR 05-DEC-2000; 2000US-0251030.  
PR 05-DEC-2000; 2000US-0251037.  
PR 05-DEC-2000; 2000US-0251988.  
PR 05-DEC-2000; 2000US-0256719.  
PR 06-DEC-2000; 2000US-0251479.  
PR 08-DEC-2000; 2000US-0251856.  
PR 08-DEC-2000; 2000US-0251868.  
PR 08-DEC-2000; 2000US-0251869.  
PR 08-DEC-2000; 2000US-0251988.  
PR 08-DEC-2000; 2000US-0251990.  
PR 11-DEC-2000; 2000US-0254097.  
PR 05-JAN-2001; 2001US-0259678.

PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
XX WPI: 2001-483426/52.  
DR  
XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
PT useful for preventing, diagnosing and/or treating cancers and  
PT metastasis -  
XX  
XX  
PS Disclosure: SRQ ID NO 38930; 3071pp + Sequence Listing; English.  
XX  
XX AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic  
CC activity, and can be used in gene therapy and vaccine production. (I)  
CC proteins and polynucleotides may be used in the prevention, diagnosis and  
CC treatment of diseases associated with inappropriate (I) expression. For  
CC example, they may be used to treat disorders associated with decreased  
CC expression by rectifying mutations or deletions in a patient's genome  
CC that affect the activity of (I) by expressing inactive proteins or to  
CC supplement the patient's own production of (I). Additionally, (I)  
CC polynucleotides may be used to produce the secreted (I), by inserting  
CC the nucleic acids into a host cell and culturing the cell to express the  
CC protein. (I) proteins and polynucleotides may be used to prevent,  
CC diagnose and treat immune/hematopoietic-related diseases, especially  
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703  
CC to AAK87694 represent human immune/hematopoietic antigen genomic  
CC sequences from the present invention. AAK54942 to AAK54950 and AAM2169  
CC represent sequences used in the exemplification of the present invention.  
XX  
SQ Sequence 9453 BP; 2869 A; 2071 C; 2294 G; 2219 T; 0 other;

Query Match 31.5%; Score 281.4; DB 22; Length 9453;  
Best Local Similarity 99.6%; Pred. No. 4.5e-65;  
Matches 282; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 612 agaggaacaaagaggaagaaagagcagcgttggaltgacctgaatgaagaattctga 671  
DB 8949 ACAGGCAAAAGAGAGAGAAAGAGAGAGCGCTTGGGATTGCGTGAAGTTCCTGA 8890  
OY 672 tacttttgcttccagtggttccattctctctctctcttcttggtgcaatatatgacct 731  
DB 8889 TACTTTCGTTCTCCAGTCTTTTCCATTCTCTCTTCTTCTTGACATATATCCGA 8830  
OY 732 aatgcacatcatatgctcagtcctcgcgaatgaagagcatgtatcccaagtaca 791  
DB 8829 AATGCACATCATATGCTCCCTCGCTCCCAATGAGAGGACATGATCCCAAGTACA 8770  
OY 792 tccatgaactgcgcgaagcagttgaactatgctggttcaagcttaaggtgtgtgtt 851  
DB 8769 TCCATGAACATGCGGAGCAGTGTGACTTATCTCTGTTACGCTTAAAGCTGTGTGTT 8710  
OY 852 tggtttttgatgt 894  
DB 8709 TGGTTTGTGATTATGTTGCTGTGTATATAAAAAAATAGAAAA 8667

RESULT 14  
AAV89379  
ID AAV89379 standard: CDNA; 266 BP.  
XX  
XX AAV89379;  
AC  
XX  
XX 15-FEB-1999 (first entry)  
DE  
XX  
XX EST clone CL152.  
XX  
XX Human; secreted protein; expressed sequence tag; EST; haematopoiesis;  
KM tissue growth; activin; inhibin; chemotaxis; chemokinesis; haemostatic;  
KM receptor; ligand; thrombolytic; anti-inflammatory; cadherin; anti-tumour;  
KM gene therapy; ss.  
XX

OS Homo sapiens.  
XX  
XX WO9845436-A2. (618 pp)  
XX  
XX 15-OCT-1998.  
PD  
XX  
XX 10-APR-1998; 98WO-US06955.  
PF  
XX  
XX 10-APR-1997; 97US-0838821.  
PR  
XX  
XX (GENV ) GENETICS INST INC.  
PA  
XX  
XX Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D;  
PI Racie LA, Spaulding V, Treacy M;  
XX  
XX WPI: 1999-070077/06.  
DR  
XX  
XX New polynucleotides encoding human secreted proteins - derived from  
PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,  
PT ovary, pituitary, retina and colon cDNA libraries.  
XX  
XX Claim 1; Page 199; 618pp; English.  
XX  
XX The present sequence represents a human expressed sequence tag (EST).  
CC The polynucleotide, which is a secreted EST, and the encoded protein  
CC are predicted to have useful biological activities which would make  
CC them suitable for treating, preventing or ameliorating medical  
CC conditions in humans and animals, although no supporting data is  
CC given. Suggested activities include nutritional activity, immune  
CC stimulating or suppressing activity, haematopoiesis regulating  
CC activity, tissue growth activity, activin/inhibin activity,  
CC chemotactic/chemokinetic activity, haemostatic and thrombolytic  
CC activity, receptor/ligand activity, anti-inflammatory activity,  
CC cadherin/tumour invasion suppressor activity, tumour inhibition  
CC activity. The polynucleotide may also be useful for gene therapy.  
XX  
SQ Sequence 266 BP; 94 A; 52 C; 73 G; 47 T; 0 other;

Query Match 28.9%; Score 258.6; DB 20; Length 266;  
Best Local Similarity 98.5%; Pred. No. 1.3e-59;  
Matches 261; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 21 caagatgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 80  
DB 2 caagatgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc 61  
OY 81 atgcttgcgtggt 140  
DB 62 atgcttgcgtggt 121  
OY 141 ggcatactctggaagacaagcagcagcagcagcagcagcagcagcagcagcagcagcag 200  
DB 122 ggcatactctggaagacaagcagcagcagcagcagcagcagcagcagcagcagcagcag 181  
OY 201 aacagaggaagaagaacaagaagccatgagctccctgtcaagaaggaagaaacccctga 260  
DB 182 aacagaggaagaagaacaagaagccatgagctccctgtcaagaaggaagaaacccctga 241  
OY 261 aaaaactgt 285  
DB 242 aaaaactgt 266

RESULT 15  
AAK85623  
ID AAK85623 standard: CDNA; 591 BP.  
XX  
XX AAK85623;  
AC  
XX  
XX 06-SEP-1999 (first entry)  
DT  
XX  
XX Novel CDNA sequence from a mouse blastocyst cDNA library.  
DE

Search completed: June 19, 2002, 14:22:59  
Job time: 5242 sec

XX Mouse; blastocyst; cDNA library; ss.  
XX Mus sp.  
OS JP11164691-A.  
XX  
XX 22-JUN-1999.  
XX  
XX 14-APR-1998; 98JP-0103115.  
XX  
XX 03-OCT-1997; 97JP-0271781.  
XX  
XX (RIKA ) RIKAGAKU KENKYUSHO.  
XX  
XX WPI; 1999-411831/35.  
XX  
XX New blastocyst cDNA - useful for library construction  
XX  
XX Claim 1; Page 6; 41p; Japanese.  
XX  
XX AX85621-X85746 represent novel cDNA sequences that are isolated from a  
XX mouse blastocyst cDNA library. The cDNA library was constructed from  
XX C57Bl/6 mice. The sequence can be used as a source of primers, probes  
XX and complementary DNA sequences.  
XX  
XX Sequence 591 BP; 177 A; 82 C; 139 G; 172 T; 21 other;

Query Match 25.9%; Score 231.2; DB 20; Length 591;  
Best local Similarity 69.9%; Pred. No. 4.1e-52;  
Matches 405; Conservative 0; Mismatches 147; Indels 27; Gaps 7;

QY 323 ctgagagaatgcagaagagctgaacgattcctctgagcttgagagtaaga 382  
DB 18 cagaatganagaagcagaaggggtgaagattcaataaaccctgaagc-tggagagtaaga 76  
QY 383 aagctgcgcggcagctgagcttgagattcttcagttccacaagaagctgcatctg 442  
DB 77 aggtctgcgcgg--nggttaagttggaatttttcagttccacaagaangttttnt---tg 131  
QY 443 ataacaaacctatgtaacttgataagctgaaggaagagctcaagaattggttga 502  
DB 132 gacacnagccnmtgttaacnltgtaaanlaagggaaagggcacagaga-tggggnng 190  
QY 503 atgctcttcaatctccagaagctgaagatgataaactgaagaagaagaagagagc 562  
DB 191 atnttcttccatnucnagaagctgggagatgataagctgaagaacggaagagaga 250  
QY 563 gatttgagattgtcacagattcagctgaactggaaccacagagatatagaggaaga 622  
DB 251 gatnnggattgtgacaagattcagatggaactggaaccacagagatatagaggaaga 310  
QY 623 agaggaagaagcagagcgttggagctgctgatagaagaagctcctgatacttctgt 682  
DB 311 aaagaagaagagcagagcgttggagctgatagaagaagctcctgatacttctgt 367  
QY 683 ctccaggttttccattctctctctctctctgtgtaacatatatgacctaaatgcaagtc 742  
DB 368 ccatagtgttttccattctcaaatlttgtgttttataatatacacacaccctac 427  
QY 743 at-----gtgcctacgtctcctcgcgaatgaggaagcattacccacag 787  
DB 428 ctactactatttacataacacagtcacatgctccacagtgaggaagcattacgtttg 487  
QY 788 tacatcatgagactgcgcagcagcatttgactatgtcgttccagctttaagttgtgt 847  
DB 488 tacatccttgattcagatcagcatttatttaactgctttnngcgtttaagattgtgt 547  
QY 848 gttttgtttttga--ttatgttctgtttaataaaaa 884  
DB 548 ggtttgtttttaattattttgttataataaaaa 586

**THIS PAGE BLANK (USPTO)**